Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Hodgkin's Disease

High-dose chemotherapy with autologous stem cell transplantation is an effective treatment of primary refractory Hodgkin's disease. Retrospective study of the Polish Lymphoma Research Group

Bone Marrow Transplantation volume 30, pages 29–34 (2002)Cite this article

Abstract

We analysed the treatment outcome of primary refractory HD patients managed with high-dose chemotherapy and haematopoietic cell transplantation. Data of 65 adult patients who underwent HDC/ASCT in nine Polish centres for primary resistant Hodgkin's disease between June 1991 and July 2000 were collected retrospectively. Response rate to HDC/ASC: CR, 54%; PR, 20%; less than PR, 15%; early deaths, 11%. Actuarial 3-year OS and PFS were 55% and 36%, respectively. In multivariate analysis, lack of bulky lymph nodes and use of immunotherapy were favourable factors for both OS and PFS. IPF <3 at the time of transplantation was predictive for PFS. However, the prognostic impact of immunotherapy should be interpreted with caution since this group included more patients who achieved CR after HDC/ASCT. The results of HDC/ASCT are encouraging and confirm earlier findings. The role of immunotherapy should be further investigated in prospective trials.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Diehl V, Franklin J, Hasenclever D et al. BEACOPP a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group J Clin Oncol 1998 16: 3810 3821

    Article  CAS  PubMed  Google Scholar 

  2. Horning SJ, Williams J, Bartlett N et al. Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group pilot study E1492 J Clin Oncol 2000 18: 972 980

    Article  CAS  PubMed  Google Scholar 

  3. DeVita VT Jr, Simon RM, Hubbard SM et al. Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute Ann Intern Med 1980 92: 587 595

    Article  PubMed  Google Scholar 

  4. Bonfante V, Santoro A, Viviani S et al. Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD J Clin Oncol 1997 15: 528 534

    Article  CAS  PubMed  Google Scholar 

  5. Josting A, Rueffer U, Franklin J et al. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group Blood 2000 96: 1280 1286

    CAS  PubMed  Google Scholar 

  6. Reece DE, Barnett JD, Shepherd DE et al. High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP 16–213 with or without cisplatin (CBV ± P) and autologous transplantation for patients with Hodgkin's disease who fail to enter complete remission after combination chemotherapy Blood 1995 86: 451 456

    CAS  PubMed  Google Scholar 

  7. Andre M, Henry-Amar M, Pico J-L et al. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study J Clin Oncol 1999 17: 222 229

    Article  CAS  PubMed  Google Scholar 

  8. Lazarus HM, Rowlings PA, Zhang M-J et al. Autotransplant for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry J Clin Oncol 1999 17: 534 545

    Article  CAS  PubMed  Google Scholar 

  9. Sweetenham JW, Carella AM, Taghipour G et al. High-dose chemotherapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation J Clin Oncol 1999 17: 3101 3109

    Article  CAS  PubMed  Google Scholar 

  10. Josting A, Reiser M, Rueffer U et al. Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure? J Clin Oncol 2000 18: 332 339

    Article  CAS  PubMed  Google Scholar 

  11. Hasenclever D, Dhiel V . A prognostic score for advanced Hodgkin's disease New Engl J Med 1998 339: 1506 1514

    Article  CAS  PubMed  Google Scholar 

  12. Schemper M, Smith TL . A note on quantifying follow-up in studies of failure time Control Clin Trials 1996 17: 343 346

    Article  CAS  PubMed  Google Scholar 

  13. Longo DL, Duffey PL, Young RC et al. Conventional dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure J Clin Oncol 1992 10: 210 218

    Article  CAS  PubMed  Google Scholar 

  14. Yuen AR, Rosenberg SA, Hoppe RT et al. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent and refractory Hodgkin'sdisease Blood 1997 89: 814 822

    CAS  PubMed  Google Scholar 

  15. Reece DE, Connors JM, Spinelli JJ et al. Intensive therapy with cyclophosphamide, carmustine, etoposide ± cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy Blood 1994 83: 1193 1199

    CAS  PubMed  Google Scholar 

  16. Crump M, Smith AM, Brandwein J et al. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: Importance of disease status at transplant J Clin Oncol 1993 11: 704 711

    Article  CAS  PubMed  Google Scholar 

  17. Horning S, Chao JN, Negrin RS et al. High-dose therapy and autologous haematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices Blood 1997 89: 801 813

    CAS  PubMed  Google Scholar 

  18. Nademanee A, O'Donnell MR, Snyder DS et al. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed or refractory Hodgkin's disease: results in 85 patients with analysis of prognostic factors Blood 1995 85: 1381 1390

    CAS  PubMed  Google Scholar 

  19. Lumley MA, Milligan DW, Knechtli CJC et al. High lactate dehydrogenase level is associated with an adverse outlook in autografting for Hodgkin's disease Bone Marrow Transplant 1996 17: 383 388

    CAS  PubMed  Google Scholar 

  20. Burns LJ, Daniels KA, McGlave PB et al. Autologous stem cell transplantation for refractory and relapsed Hodgkin's disease: factors predictive of prolonged survival Bone Marrow Transplant 1995 16: 13 18

    CAS  PubMed  Google Scholar 

  21. Chopra R, McMillan KA, Linch DC et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease: a single-center eight-year study of 155 patients Blood 1993 81: 1137 1145

    CAS  PubMed  Google Scholar 

  22. Rapoport AP, Rowe JM, Kouides PA et al. One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: value of pretransplant disease status for predicting outcome J Clin Oncol 1993 11: 2351 2361

    Article  CAS  PubMed  Google Scholar 

  23. Aviles A, Diaz-Maqueo JC, Talavera A et al. Maintenance therapy with interferon alfa 2b in Hodgkin's disease Leuk Lymphoma 1998 30: 651 656

    Article  CAS  PubMed  Google Scholar 

  24. Nagler A, Ackerstein A, Or R et al. Immunotherapy with recombinant human interleukin-2 and recombinant interferon-α in lymphoma patients postautologous marrow and stem cell transplantation Blood 1997 89: 3951 3959

    CAS  PubMed  Google Scholar 

  25. Nagler A, Ackerstain A, Czyz J et al. Lymphokine-mediated immunotherapy with recombinant interleukin-2 (rIL-2) and recombinant interferon alpha (IFN-α versus no immunotherapy following autologous peripheral blood stem cell transplantation (ASCT) for Hodgkin's disease: an interim analysis of a multi-center two-arm randomised study Exp Hematol 29:: (Suppl. 1) 63

  26. Jack FR, Angys B, Taylor PRA . Prognostic score for Hodgkin's disease New Engl J Med 1999 340: 1288 1289 (letter)

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Prof Jacek Jassem and Dr Jan Maciej Zaucha (Medical University of Gdańsk) for an in depth discussion of the manuscript, Dr Richard Szydlo (Hammersmith Hospital, London) for valuable comments on statistical analysis and Mrs Agnieszka Pliszka (Medical University of Gdańsk) for data management.

Author information

Authors and Affiliations

  1. Medical University, Gdańsk, Poland

    J Czyż, A Hellmann, R Dziadziuszko & W Knopińska-Posłuszny

  2. University of Medical Sciences, Poznań, Poland

    J Hansz & J Goździk

  3. Silesian Medical University, Katowice, Poland

    J Hołowiecki, B Stella-Hołowiecka & Ł Kachel

  4. The Chaim Sheba Medical Centre, Tel-Hashomer, Israel

    A Nagler

  5. Maria Skłodowska-Curie Memorial Cancer Centre-Institute of Oncology, Warsaw, Poland

    J Meder, J Walewski & E Lampka

  6. Central Military Hospital, Warsaw, Poland

    K Sułek & W Sawicki

  7. K Dłuski Hospital-Institute of Immunology and Experimental Therapy, Wrocław, Poland

    A Lange, K Forgacz, K Suchnicki & T Pacuszko

  8. Collegium Medicum Jagiellonian University, Cracow, Poland

    A Skotnicki, P Mensah & W Jurczak

  9. Medical University, Wrocław, Poland

    K Kuliczkowski, T Wróbel & G Mazur

  10. Medical University, Lublin, Poland

    A Dmoszyńska & M Wach

  11. Copernicus Memorial Hospital-Medical University, Łódź, Poland

    T Robak & K Warzocha

Authors
  1. J Czyż
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Hellmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R Dziadziuszko
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J Hansz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J Goździk
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J Hołowiecki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. B Stella-Hołowiecka
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ł Kachel
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. W Knopińska-Posłuszny
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A Nagler
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. J Meder
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. J Walewski
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. E Lampka
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. K Sułek
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. W Sawicki
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. A Lange
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. K Forgacz
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. K Suchnicki
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. T Pacuszko
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. A Skotnicki
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. P Mensah
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. W Jurczak
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. K Kuliczkowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. T Wróbel
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. G Mazur
    View author publications

    You can also search for this author in PubMed Google Scholar

  26. A Dmoszyńska
    View author publications

    You can also search for this author in PubMed Google Scholar

  27. M Wach
    View author publications

    You can also search for this author in PubMed Google Scholar

  28. T Robak
    View author publications

    You can also search for this author in PubMed Google Scholar

  29. K Warzocha
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Czyż, J., Hellmann, A., Dziadziuszko, R. et al. High-dose chemotherapy with autologous stem cell transplantation is an effective treatment of primary refractory Hodgkin's disease. Retrospective study of the Polish Lymphoma Research Group. Bone Marrow Transplant 30, 29–34 (2002). https://doi.org/10.1038/sj.bmt.1703590

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703590

Keywords

This article is cited by

Search

Advanced search

Quick links